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Modeling glioblastoma heterogeneity as a dynamic
network of cell states
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Abstract
Tumor cell heterogeneity is a crucial characteristic of malignant
brain tumors and underpins phenomena such as therapy resis-
tance and tumor recurrence. Advances in single-cell analysis have
enabled the delineation of distinct cellular states of brain tumor
cells, but the time-dependent changes in such states remain poorly
understood. Here, we construct quantitative models of the time-
dependent transcriptional variation of patient-derived glioblas-
toma (GBM) cells. We build the models by sampling and profiling
barcoded GBM cells and their progeny over the course of 3 weeks
and by fitting a mathematical model to estimate changes in GBM
cell states and their growth rates. Our model suggests a hierarchi-
cal yet plastic organization of GBM, where the rates and patterns
of cell state switching are partly patient-specific. Therapeutic
interventions produce complex dynamic effects, including inhibi-
tion of specific states and altered differentiation. Our method
provides a general strategy to uncover time-dependent changes in
cancer cells and offers a way to evaluate and predict how therapy
affects cell state composition.
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Introduction
During the last two decades, there has been a multifaceted debate
on the time-dependent variation of differentiation states in tumor
cells. According to the cancer stem cell model, both solid tumors
and leukemias tend to follow developmental hierarchies, with stem-
like cells at the apex (Reya et al, 2001; Pardal et al, 2003; Singh
et al, 2004. A complementary set of ideas, often referred to as tumor
cell plasticity, emphasize a less structured variation, whereby tumor
cells can switch multi-directionally between stem-like and differenti-
ated states, or between migratory and proliferative states, tending
toward stochastic equilibrium (Gupta et al, 2011; Gerlee & Nelander,
2012; Dirkse et al, 2019). Crucially, the two perspectives have dif-
ferent therapeutic implications; whereas the cancer stem cell model
logically implies that targeting the stem-like cells might eradicate
the tumor (Dingli & Michor, 2006), the latter (plasticity) model
suggests that tumor growth and therapeutic responses will depend
in a complex and quantitative manner on the specific switching
patterns and rates (Gupta et al, 2011; Gerlee & Nelander, 2012). This
study aims to establish a method that can resolve and quantify the
time-dependent heterogeneity of tumor cells, both during normal
growth and during treatment.
Glioblastoma (GBM) is a malignant brain tumor characterized by
short survival and a lack of effective therapeutic options (Lesueur
et al, 2019). Patient tumors can be divided into three gene expres-
sion subtypes termed proneural, mesenchymal, and classical (Wang
et al, 2018), but the heterogeneity is not restricted to variation
between patients. Already in the 1930s, it was noted that GBMs
exhibit a high degree of cell-to-cell heterogeneity, as evident from
distinct histological structures within the tumor (Scherer, 1938;
Puchalski et al, 2018). Recent explorations of GBM by single-cell
RNA profiling have demonstrated that GBM cells exist in a variety
of transcriptional states, indicating differences in neuronal and glial
differentiation, as well as differential activity of gene programs
involved in mesenchymal transformation and cell cycling (Patel
et al, 2014; Neftel et al, 2019). It is expected that this diversity is a
key factor underlying tumor recurrence and response to therapy
(Bedard et al, 2013), but despite our increasing ability to detect
GBM differentiation states, their time-dependent variation remains
poorly understood. Whereas xenograft studies have supported a
hierarchical organization, driven by a subpopulation of CD133+
tumor-initiating cells (Singh et al, 2004; Lan et al, 2017), several
lines of evidence, including time-lapse microscopy, RNA velocity
measurements, and in vivo lineage tracing, support a less hierarchi-
cal (plastic) organization (Farin et al, 2006; Gerlee & Nelander,
2012; Dirkse et al, 2019; Neftel et al, 2019; Wang et al, 2019;
Couturier et al, 2020). Thus, further clarifying the dynamics of
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transcriptional states in GBM will have important consequences for
therapy development and our understanding of the disease.
Herein, we describe a quantitative strategy to uncover both hier-
archical variation and plastic variation of GBM differentiation states,
based on the integration of molecular barcodes, single-cell profiling,
and mathematical modeling. Applied to cells from a selected set of
patient-derived GBM cell lines, our proposed state transition and
growth (STAG) model achieves de novo identification of transcrip-
tional states and provides estimates of state-specific growth rates
and the frequencies of transitions between the states. The fitted
STAG models are hierarchically structured networks (including a
top state) with multi-directional switching between intermediate
states that recapitulate specific neural cell types. To demonstrate
how our strategy can account for the effects of therapies, we extend
our model to measure how treatment with a clinically used drug (te-
mozolomide) and a growth-inhibiting cytokine (BMP4) change the
cell state transitions. We further propose a mathematical criterion to
predict how drugs affect population growth and state composition,
based on the eigendecomposition of the matrix of cell state transi-
tion rates.
Altogether, our results introduce a new method to model mathe-
matically the cell state changes in solid tumor cells under normal
growth and therapeutic intervention. We expect that our model will
have interesting applications in the assessment of novel therapies
and in the formulation of strategies to enhance the effects of stan-
dard therapies.
Results
The goal of the developed method is to measure how the transcrip-
tional state of individual GBM cells changes over time and to esti-
mate how such changes are affected by treatment. Previous reports
(Gupta et al, 2011; Dirkse et al, 2019; Neftel et al, 2019) have
demonstrated that single cells, or purified populations of tumor cells
(consisting of a single state), can give rise to a mixture of states,
implying that transitions between cell states have occurred. Here,
we present a more general method that does not require the purifi-
cation of cells in any particular state. Our strategy comprises three
main steps (Fig 1A). First, we introduce a set of unique heritable
barcodes into a culture of patient-derived cells. Next, we propagate
the cells in culture, sampling a fraction of cells at regular time inter-
vals and use single-cell RNA sequencing to determine both the tran-
scriptome and the barcode of each cell. Our algorithm, STAG, is
subsequently used to build a model of the data, which identifies the
cell states, their growth rates, and the structure and rates of the
transitions. With particular experimental and computational exten-
sions, described below, STAG can also measure how specific drugs
alter the cell state transitions and predict interventions most likely
to reduce net tumor growth.
Lineage tracing and profiling of barcoded glioblastoma cells
As a first test case for our approach, we chose the well-characterized
GBM cell culture U3065MG, derived from a 77-year-old male
patient. U3065MG cells classify as mesenchymal subtype, are TP53
and IDH1 wild type, form infiltrative macroscopic tumors in vivo,
and harbor a subset of clonogenic cells that can give rise to both
primary and secondary cultures (Xie et al, 2015; Segerman et al,
2016). We transduced passage 6 U3065MG cells with a lentiviral
mRNA barcode library (Adamson et al, 2016) at a low (0.1) multi-
plicity of infection to ensure that a majority of transduced cells
would carry a single unique barcode. An initial population of 2,500
barcoded cells was subsequently grown for 21 days in vitro. Cells
were passaged each week; on each passage, we harvested 80% of
the culture for single-cell RNA sequencing and kept the remaining
cells (20%) in culture. This way, we obtained a series of observa-
tions for cells on days 7, 14, and 21. The fraction of sampled cells
(80%) was chosen to guarantee a sufficiently big random sample
of cells with each barcode, and the time scale of the experiment
(21 days) aimed to capture gradual changes in cell differentiation
state (see Appendix for details). As a reference point, to validate
the barcoding, we also included a separate sample of cells immedi-
ately after barcoding (0 days). No apparent batch effects or skew-
ness of the transcriptome due to the barcoding could be found
(Appendix Fig S1).
We first analyzed the number of cells carrying a particular
barcode, i.e., the clone size. As expected, the clone size was
precisely 1 immediately after barcoding. As the experiment
progressed, the variation of observed clone sizes increased (Fig 1B),
and the number of unique remaining clones decreased, suggesting
the extinction of some clones (Fig 1C). To account for these trends,
we applied a stochastic model of clonal growth with fixed cell prolif-
eration and death rates (formally, a Galton–Watson process (Wat-
son & Galton, 1875)) for each clone. A simulation of such a process
fitted to our data recapitulated with good accuracy the experimental
observations of dispersing clone sizes and the number of observed
barcodes per time point (Fig 1D and E).
To explore biological factors that might influence clone size, we
analyzed the differential gene expression between cells belonging to
large vs small clones using gene set enrichment analysis (GSEA).
Small clones were characterized by, e.g., up-regulation of the
▸Figure 1. Resolving the plasticity of GBM cells.A Overview. In the STAG procedure, barcoded tumor cells are sampled at multiple time points and profiled by single-cell RNA sequencing, followed by mathematical
modeling to identify (i) the states and their growth rates, (ii) the patterns and rates of the state transitions, (iii) how drugs affect cell states, and (iv) analysis of cell
population stability and long-term projections of cell state compositions.
B Clone sizes of barcoded U3065MG cells at 0–21 days. X-axis, barcodes; Y-axis, number of cells containing each barcode.
C Venn diagram of number of barcodes detected at 7, 14, and 21 days.
D, E Simulation of the experiment in (B,C) using a Galton–Watson process with a fixed growth and death rate.
F Enriched gene sets in small and large clones, respectively, using Gene Set Enrichment Analysis (GSEA). Normalized enrichment scores (NES) and q-values are
indicated in the figure.
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Hallmark p53 pathway, consistent with p53 being a tumor suppres-
sor, whereas the larger clones upregulated SOX2 and stemness
signatures (Fig 1F), consistent with these clones having a higher
proliferation rate. We conclude that our barcoding strategy can trace
GBM clonal growth with accuracy and that the transcriptional pro-
file and clonal growth rate were correlated, warranting further
investigation.
The state transition and growth model
Next, we developed a computational model to integrate variation in
cell state and cell growth. Mathematically, a natural way to repre-
sent state transitions in cells is by Markov chain modeling (Gupta
et al, 2011; Dirkse et al, 2019). Markov chains can represent both
hierarchical switching and multi-directional switching, but do not
account for cell proliferation and death. This is problematic since,
for instance, the rapid proliferation of one state may be
misinterpreted as transitions toward that state. We, therefore,
considered a model based on Gerlee and Nelander (2012), in which
growing GBM cells alternate between 2 states. This 2-state model,
however, is not consistent with recent data suggesting multiple
states in GBM cells (Neftel et al, 2019). Here, we propose a more
general class of models (Box 1) to integrate cellular state transitions
and growth, based on four assumptions:
• Tumor cells exist in either of k transcriptional states.
• Each of the k states has specific proliferation and death rates.
• Tumor cells randomly transit between states at specific rates.
• An externally applied drug can alter the transition parameters, the
growth parameters, or both.
Together, these rules describe a stochastic model which can be
simulated, e.g., using Gillespie’s method (Gillespie, 1976). Our
model contains previous models as special cases; for instance, when
Box 1. The State Transition and Growth (STAG) model
Key model concepts and equations. The state transition and 
growth model is based on 4 rules: 
 1) tumor cells exist in either of k states, 
 2) each of the k states has a specific proliferaton and death  
 rate, 
 3) tumor cells stochastically transit between the states at  
 some fixed average rate and 
 4) an externally applied drug can alter the transition rates,  
 the growth rates or both. 
The transition rates in (3) are constrained to be non-negative to 
estimate transitions in both directions. The system is approximat-
ed by continuous first order rate equations, whereby all the transi-
tion and growth rates are summarized by a k * k matrix, A, which 
gives the explicit solution 
X(ts ) = e
AtX(ts-1 )                                    (1)
where X(ts) and X(ts-1) are the state distribution over barcodes at 
time ts and ts-1, respectively, and e denotes the matrix exponen-
tial. To illustrate the transition matrix A and the parameters that 
can be derived from it, we use the specific case of k = 2 :
Using a first degree approximation of the matrix exponential 
(Materials and Methods), the sum-of-squares error over all 
barcodes is given by
where ηs is an adjustment factor for harvesting of cells. E(X,A) is 
minimized using convex optimization to find A, given the experi-
mental data.
To capture the treatment-specific component of the transition 
network, the transition matrix was redefined as consisting of one 
joint and one treatment-specific component, expressed as
   Atreatment = Auntreated + ∆Atreatment    (3)
Auntreated represents the baseline network, i.e. that of untreated 
cells, and ∆Atreatment the changes in transition and growth rates due 
to treatment: 
growth. We note that if we let X(t) denote the total number of 
tumor cells in all states, i.e. X(t) = X1 + X2 +,...,+ Xk, the matrix A 
fully denotes how X(t) will change over time. Theory for linear 
dynamical systems (Varfolomeev & Lukovenkov, 2018) implies 
that X will have a steady state if and only if  
Re(λi) ≤ 0, i = 1, 2, ..., k                             (4)
where λi are the eigenvalues of A. We can compute the eigenval-
ues of A to determine if the net growth is stable. Furthermore, we 
can predict a minimal intervention ∆A that stabilizes the cell 
population by formulating a convex optimixation problem and 
solve for the minimal change needed to the A-matrix to obtain a 
stable system, which satisfies the convex relaxation of stability, 










tion needed to stabilize the tumor cell population, i.e. suppress 
(2)
(5)~
The A-matrix can be further used to predict the minimal interven-
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k = 1 (a single state), it corresponds to a standard stochastic model
of clonal growth (Galton–Watson process, as above); when states
represent migratory and proliferative GBM cells (k = 2), it is equiva-
lent to the Gerlee and Nelander (2012) two-state model; and when
the model has multiple states and the proliferation and death rates
are zero, it is equivalent to the Markov chain model (Gupta et al,
2011; Dirkse et al, 2019).
Note that our model makes no prior assumptions regarding the
number and type of states, or how the states are connected. Based
on the data, it can be used to represent either a hierarchical organi-
zation, as well as one characterized by multi-directional transitions.
Fitting state transition and growth models to experimental data
Given the above STAG model, we developed an efficient method
for fitting its parameters from barcoded single-cell RNA profiling
data, as follows. We first note that all the transition and growth
rates are summarized by a k times k matrix, A¼ aij, which can be
thought of as a network map of the cell state transitions (Box 1).
Specifically, the non-diagonal elements aij, i≠j of A represent the
transition rate from state j to state i. The column sums of A, in
turn, represent the net growth of each state (Box 1). Given observa-
tional data, our algorithmic goal is to obtain estimates of all the
elements of A. We do this by a convex optimization algorithm,
which minimizes a global error function over the full data set,
comprising the state distributions of each barcode at days 7, 14,
and 21 (Materials and Methods, Equations 6 and 7). Due to the
convex formulation, a complete and unique solution can be rapidly
obtained (fractions of a second). To benchmark our algorithm, we
performed a large number of simulations, in which STAG models
of different sizes (k) and connectivity were simulated under dif-
ferent experimental designs. The simulations supported that the
particular experimental setup, a 3-week experimental design with
sampling every 7 days and a 6-state system (discussed below),
could identify the elements of A (i.e., the transitions and growth
rates) with low error (Appendix Fig S2).
State transitions and growth dynamics of U3065MG cells
To construct a STAG model of U3065MG cells, we first divided all
profiled cells into discrete cell states, based on their RNA profiles.
We assigned states by consensus k-means clustering (Fig 2A,
Dataset EV1). The number of states (k = 6) was selected by boot-
strapping methods (Appendix Fig S3). Relating states to clone sizes,
we found all six states present in clones with at least 37 detected
cells (Fig 2B). Moreover, cells from all six states could be found at
each time point (Fig 2C).
The best-fitting STAG model derived from the data contained
transitions ranging from 0.01 to 0.3 transitions per day (Fig 2D).
The STAG network of detected transitions in U3065MG cells was
hierarchically organized (Fig 2E) with substantial differences in
growth rates of each state (Fig 2F). For instance, the top state (1)
grew at 0.29 divisions/day and had only outgoing transitions. Imme-
diately downstream, state 2 had the fastest growth rate (0.79 divi-
sions/day), followed by state 3–5 with growth rates between 0.12
and 0.25 divisions/day. We found several cases of multi-directional
switching between states 2–5. At the bottom of the hierarchy, state
6 had a negative growth rate and not outgoing transitions and thus
acted as a sink state in the STAG network.
We performed two additional experiments to confirm that transi-
tions occur in the U3065MG cells. In the first, we isolated state 1
cells by fluorescence-activated cell sorting (FACS), based on the
surface markers CD24, CD44 (high in states 1 and 4), and HLA-DR
(low in state 1, high in state 4; Fig EV1A). We observed a gradual
phenotypic drift away from the purified state 1 cell population into,
e.g., state 4 (CD24high/CD44high/HLA-DRhigh; Figs 2G and EV1B).
Second, we analyzed a U3065MG-derived clonal culture, U3065MG-
C475 (Segerman et al, 2016), by single-cell RNA sequencing and
assigned each cell one of the six states using single-sample GSEA
(ssGSEA). We found that the clonal U3065MG-C475 culture
contained all six states found in the parental U3065MG culture
(Fig 2H). These experiments further support that cell state transi-
tions take place in the U3065MG cell culture.
U3065MG cell states have distinct functional signatures
We carried out GSEA to obtain a functional profile for each state,
based on its differentially expressed genes (Fig 3A), considering
both the MSigDB Hallmark pathways and a collection of gene signa-
tures relevant to GBM biology (Wang et al, 2018; Zhong et al, 2018;
Neftel et al, 2019; Weng et al, 2019; Couturier et al, 2020; Garofano
et al, 2021). The GSEA identified the top state 1 as the most
mesenchymal state, matching signatures by, e.g., Neftel et al (2019)
and Wang et al (2018). State 2, in turn, was enriched for proneural
markers and neural progenitor profiles (Zhong et al, 2018; Garofano
et al, 2021) and an up-regulation of cell cycle-related gene sets.
Thus, state 2 resembles a rapidly proliferating progenitor with a
proneural profile. States 1 and 2 were both enriched for markers of
the glial progenitor-like cells defined by Couturier et al (2020),
consistent with a position of these states at the top of the hierarchy.
◀ Figure 2. State dynamics of cells from the mesenchymal U3065MG GBM cell line.
A UMAP embedding of single U3065MG cells colored according to transcriptional cell state assignment.
B Average number of states represented in each clone with increasing clone size. X-axis, clone size; Y-axis, average number of states.
C UMAP embedding of cell state distribution at each experimental time point. State colors as in (A).
D Heatmap of the U3065MG state transition and growth matrix A derived from the STAG model.
E Estimated network of state transitions in the U3065MG cell line. The thickness of the arrows correlates with the rate of transition (number of transitions per day).
F STAG estimates of growth rates (cell divisions per day) for U3065MG states 1–6. Error bars indicate the 90% confidence interval, based on 1,000 bootstrap replicates.
G Enrichment of the U3065MG state 1 cell population (CD24high/CD44high/HLA-DRlow) using FACS cell sorting. Cells were monitored by flow cytometry over 3 weeks, and
a gradual phenotypic drift, e.g., toward state 4 (CD24high/CD44high/HLA-DRhigh), could be observed. See also Fig EV1.
H scRNA sequencing of a U3065MG-derived clonal culture (clone 475) detected all six states of the U3065MG mother cell line. U3065MG-C475 cells were scored against
U3065MG state 1–6 signatures using ssGSEA.
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Figure 3. Characterization of states in the mesenchymal U3065MG GBM cell line.
A GSEA of the gene signatures for each of the six U3065MG states. Blue and red indicate negative and positive enrichments of the pathway. Size of the dot indicates
significance (proportional to the GSEA false discovery rate [FDR] q-value). Gene sets without PMID reference were obtained from the MSigDB Hallmarks database of
gene sets. Abbreviations: oligodendrocyte progenitor cell (OPC), neural progenitor cell (NPC), mesenchymal (MES), astrocyte (AC), neuronal (NEU), mitochondrial (MTC),
proliferative/progenitor (PPR).
B Survival analysis of TCGA GBM patients estimated by Cox’s proportional hazards model, with enrichment score of states 1–6 as independent covariate. Shaded areas
indicate 95% confidence intervals, calculated as  1.96 * standard error (SE)). HR, hazard ratio.
Source data are available online for this figure.
ª 2021 The Authors Molecular Systems Biology 17: e10105 | 2021 7 of 19
























































































































8 of 19 Molecular Systems Biology 17: e10105 | 2021 ª 2021 The Authors
Molecular Systems Biology Ida Larsson et al
The states 3 and 5 matched oligodendrocyte precursor cell (OPC)
signatures described by Neftel et al (2019) and Zhong et al (2018) as
well as the Hallmark mesenchymal transition signature. Although
states 3 and 5 were similar, enrichment for the mitotic spindle was
found in state 3, which was absent in state 5. Also when cluster
number was reduced, states 3 and 5 remained separate (Fig EV2),
motivating the interpretation of states 3 and 5 as two separate cell
states. State 4 matched astrocyte signatures described by Neftel et al
(2019) and Zhong et al (2018). However, its enrichment for neural
progenitor cells (Neftel NPC2) and the ability of state 4 cells to tran-
sit up in the hierarchy toward state 2 indicate that this state does
not represent terminally differentiated astrocyte-like cells. Last, state
6 was enriched for a Hallmark p53 response, and a majority of the
top marker genes of state 6 have functions linked to the inhibition
of cell proliferation, cell cycle arrest, and the apoptosis, such as
CDKN1A, GADD45A, and SOX4, which helps explain the negative
growth (Fig 2F) of state 6 (Dataset EV1).
We further related our state signatures to The Cancer Genome
Atlas (TCGA) patient cohort through ssGSEA. Cox’s proportional
hazards models were constructed using the enrichment score for
each state in each patient as the predictor variable. For U3065MG,
this revealed a significant association between a high state 1 score
and poorer survival (Cox coefficient = 2.642, P < 0.001; Fig 3B). A
weaker association was found for a high state 3 score (Cox coeffi-
cient = 1.857, P = 0.016) while remaining states were not signifi-
cantly associated with survival.
Distinct hierarchical STAG networks in cells from
different patients
To address the generality of our findings, we performed RNA profil-
ing and STAG analysis using two additional patient-derived GBM
cultures. One, U3071MG (male patient, 65 years old), was a
mesenchymal cell line chosen to be similar to U3065MG. The other,
U3017MG (female, 68 years), has classical subtype designation and
was selected to be distinct from the other two (Appendix Fig S4).
Like for the U3065MG cells, a subdivision into six states was
preferred for both U3071MG and U3017MG, as judged by consensus
clustering (Fig 4A and B; Appendix Figs S5 and S6). In the below
presentation, we denote the U3071MG states by Latin numerals (I–
VI) and the U3017MG states by letters (A–F).
The STAG network detected for U3071MG was hierarchically
structured, in a way that resembled U3065MG, although with a
higher degree of bi-directionality in its transitions (Fig 4C). For
instance, a degree of influx into the top state (state I) could be
detected, which was absent in the U3065MG cell line. In addition,
two sink states (states V and IV) with no outgoing transitions were
found. The states displayed substantial differences in growth rates,
and, just as for the U3065MG STAG network, the fastest growing
state was found second to the top in the hierarchy (state II) and the
only state with a negative growth rate was identified as one of the
sink states (state V; Fig 4E).
The U3017MG STAG network had no bi-directional switching
between states (Fig 4D). Instead, all transitions were directed down-
stream from a top state (state A) with the fastest growth rate (Fig 4F),
toward three sink states (states C, D, and E), partly via an inter-
mediate state (state B). The final state (state F) initially appeared
disconnected from the network, but when the threshold for state
transition occurrences in the network was decreased to 0.001 (corre-
sponding to 1 transition in 1,000 days) rare transitions toward state
C emerged.
To elucidate the correspondence between states from the dif-
ferent cell lines, we assigned the U3071MG and U3017MG cells to
the U3065MG states via ssGSEA. While not all states corresponded
in a 1-to-1 manner between cell lines (Fig 4G and H), we saw a
clear correspondence between the fastest growing states (state 2 in
U3065MG cells, state II in U3071MG, and state A of U3017MG). In
all cases, GSEA results showed enrichment of cell cycle-related
gene sets as well as neural progenitor-associated signatures (Garo-
fano PPR, Zhong NPCs; Fig 5A). Similarly, the top states of
U3065MG and U3071MG had clear similarities in terms of enrich-
ment of mesenchymal signatures described by Neftel et al (2019)
and Wang et al (2018). Thus, both the mesenchymal GBM cell
lines appear to be driven by a mesenchymal state at top of the
STAG network, the counterpart of which was not found in the clas-
sical cell line.
When relating the state signatures to TCGA survival, we noted
that U3071MG-state I had a significant association to poorer survival
(Cox coefficient = 1.230, P < 0.01), while the same was not true for
the top state in U3017MG (Fig EV3). Taken together, this indicates
that the top mesenchymal state in the two mesenchymal GBM cell
lines predicts survival in TCGA patients, but that a similar trend
could not be found for the rapidly proliferating, progenitor top state
in the classical GBM cell line.
GBM top states are transcriptionally similar to early embryonal
neural precursor cells
To explore the relationship between our STAG networks of GBM
and a normal neural developmental hierarchy, we compared our
state signatures with embryonic scRNA-seq-data from a recent atlas
of the embryonic human brain (Eze et al, 2021). In this atlas,
embryonic brain cells from different Carnegie stages (12–22) are
divided into 61 different clusters. We calculated the statistical over-
lap between each such embryonic cluster with our state signatures
and sorted the embryonic clusters based on the mean Carnegie time
of all cells in that cluster (Fig 5B). Interestingly, the top states in
each STAG network (U3065MG-states 1 and 2, U3017MG-states
◀ Figure 4. State dynamics of cells from the mesenchymal U3071MG and the classical U3017MG GBM cell lines.
A, B UMAP embedding of single cells from the mesenchymal U3071MG (A) and classical U3017MG (B) GBM cell lines, colored according to transcriptional state
assignments I–VI and A–F, respectively.
C, D Estimated network of state transitions in U3071MG (C) and U3017MG (D). The thickness of the arrows correlates with the rate of transition (number of transitions
per day, as in Fig 2E).
E-F State growth rates (number of cell divisions per day) in U3071MG (E) and U3017MG (F).
G, H Sankey plot of the relation between the states defined in U3065MG cells (1–6), and the states defined in U3071MG cells (I–VI) (G) and in U3017MG cells (A–F) (H).
U3071MG and U3017MG cells were scored against U3065MG state 1–6 signatures using ssGSEA.
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A and B, and U3071MG-state II) overlapped with cells from the earlier
time points in the embryonic brain atlas, while downstream states
showed a higher correlation with later time points. These results indi-
cate that the GBM cell states and state transitions partly recapitulate
the differentiation processes in the human developing brain.
Therapeutic interventions in the state transition and
growth model
Next, we aimed to explore how STAG can detect changes in cell
state transitions during treatment. For this, we carried out a barcod-
ing experiment in U3065MG cells, in which cells were exposed to
two therapeutic agents (Fig 6A). Temozolomide (TMZ) was chosen
as the standard-of-care drug and added at a concentration found in
the cerebrospinal fluid of GBM patients (1 µg/ml), to reflect a clini-
cally relevant dose (Ostermann et al, 2004). The cytokine BMP4 was
chosen for its inhibitory effect on GBM growth (Piccirillo et al, 2006;
Dalmo et al, 2020) and was administered at a dosage (1 ng/ml)
shown to elicit a receptor response (Heemskerk et al, 2019) and to
have an effect on cell fate choice (Lim et al, 2000), while not caus-
ing a complete stop of cell proliferation.
Following barcoded single-cell RNA profiling, we assigned the
previously defined states 1–6 to each of the cells and fitted a more
general version of the STAG model (Box 1), to obtain three STAG
networks (Auntreated, ATMZ, and ABMP4) for U3065MG cells under
each condition. Comparing the three models, we found that treat-
ments had distinct effects on the growth rates of each cell state
(Fig 6B). For instance, while TMZ was more effective in suppressing
the proliferative state 2, BMP4 selectively suppressed the growth of
state 5. Interestingly, both treatments led to a modest increase in the
growth of state 1. Both treatments altered the state transitions in
U3065MG cells. In BMP4-treated cells, we saw a selective decrease
in the transitions from 2 to 4 (Fig 6C and D), whereas both treat-
ments appeared to increase the rate of transitions from the neural
progenitor-like state 2 to the OPC-like state 5 (Fig 6D and E).
The observation that treatments cause detectable changes in state
growth rates and cell state transitions led us to ask whether the
STAG model can be applied to long-term projections of the cell
populations, both in terms of population size and in terms of the
relative composition of cell states. Further mathematical analysis of
the STAG model (Materials and Methods) showed that such predic-
tions can be obtained from the eigendecomposition of the STAG
network (A matrix). This standard type of mathematical matrix
decomposition results in eigenvalues and eigenvectors, both of
which have interesting interpretations in the context of our model
(Fig 6E). First, the eigenvalues tell us how the population size will
develop. Specifically, from the theory of linear dynamical systems
(Varfolomeev & Lukovenkov, 2018) the position of the eigenvalues
of A along the real axis (in the complex number plane) tell us if the
net number of cells will shrink toward zero (all eigenvalues nega-
tive), or grow exponentially (one or more positive eigenvalue). As a
concrete example, TMZ-treated U3065MG cells, exposed to a dose of
1 μg/ml, had a positive growth rate, reflected by two positive eigen-
values (Fig 6E). We could thereby ask whether a small set of
changes to transition rates might render the eigenvalues negative,
thereby implying long-term eradication of the tumor cells. To test
this idea, we adapted STAG to search for such modifications (Stabil-
ity analysis, Materials and Methods), and found reduction in transi-
tions from states 1, 2, 3, and 4 to state 5 would be required (Fig 6F).
The second use of the eigendecomposition is that if the A-matrix
has a real-valued eigenvector, this will predict the future cell state
equilibrium (Steady-state distribution, Materials and Methods). By
applying this to our STAG networks, we can predict the cell state
equilibrium for cells kept untreated (Figs 6G and EV4), as well as
for U3065MG cells during treatment with BMP4 and TMZ (Fig 6G).
We conclude that the STAG procedure can detect treatment-
specific changes in state growth rates and state transitions. The
eigendecomposition of the A matrix reflects a long-term projection
of the system, in terms of net growth and state composition.
Discussion
In this work, we have described a new strategy to assess the time-
dependent heterogeneity of malignant tumors. The proposed STAG
model quantitatively describes state transitions and growth, on a
well-defined time scale. It can also characterize the effect of thera-
pies and predict changes that would reduce tumor growth. Thereby,
the method meets a need for principled and quantitative strategies
to discuss the time-dependent heterogeneity of malignant tumors.
Applying STAG to three cases of GBM, we observed a hierarchi-
cally structured pattern of state transitions. The two mesenchymal
subtype GBM cell lines (U3065MG and U3071MG) each had a
mesenchymal top state which was followed by a downstream,
rapidly proliferating state with a neural progenitor-like profile. In
contrast, such a mesenchymal top state was not found in classical
subtype U3017MG cells, where the rapidly proliferating state was
found directly at the top. In the two mesenchymal lines, we found
evidence of multi-directional switching, which was not observed in
U3017MG cells, which were strictly hierarchical. All STAG networks
contained sink states with no outgoing transitions at the bottom of
the hierarchy. When unperturbed, our STAG models resemble the
◀ Figure 5. Characterization of the states in the mesenchymal U3071MG and the classical U3017MG GBM cell lines.
A GSEA of the gene signatures for each of the six states in U3017MG and U3071MG. Blue and red indicate negative and positive enrichments of the pathway. Size of the
dot indicates significance (proportional to the GSEA FDR q-value). Gene sets without PMID reference were obtained from the MSigDB Hallmarks database of gene sets.
Abbreviations: oligodendrocyte progenitor cell (OPC), neural progenitor (NPC), mesenchymal (MES), astrocyte (AC), neuronal (NEU), mitochondrial (MTC), proliferative/
progenitor (PPR).
B State signatures for U3065MG (1–6), U3017MG (A–F), and U3071MG (I–VI) related to embryonic cluster definitions from Eze et al. The heatmap shows enrichment
results; red and blue indicate positive and negative enrichments, respectively. The dot plot in the right panel shows mean Carnegie stage for cells in each embryonic
cluster. Barplots below the heatmap show Spearman correlation (n = 61) between the enrichment profile for each state and the Carnegie time for each embryonic
cluster. Spearman P-values are shown below barplots.
Source data are available online for this figure.
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proliferative hierarchy described by Lan et al (2017) where they use
DNA barcoding in an in vivo setting. Similar to our findings, they
see a gradual loss of barcodes over time. This can to a certain extent
be explained by the sampling strategy, where all cells representing
one barcode can be harvested at one time point by chance, and in
part by the hierarchical structure, where barcodes that tagged cells
at the bottom of the hierarchy at the experimental starting point are
expected to disappear. Our detected states are enriched for markers
found in previous studies (Zhong et al, 2018; Neftel et al, 2019;
Couturier et al, 2020), and we also find a selective match between
top states and early embryonic time points. This, together with an
association between top states and survival, lends credence to the
biological relevance of the detected state signatures.
Since microenvironmental factors are known to be important for
GBM cell state choices (Calabrese et al, 2007; Wang et al, 2018;
Neftel et al, 2019), future applications of this method should be
considered to elucidate cell state transition organization when cells
are exposed to environmental factors, such as hypoxia, or directly
in vivo. In this work, we have chosen to interrogate the effects of
the first-choice chemotherapeutic agent TMZ and BMP4, a physio-
logical factor known to inhibit GBM cell proliferation. Both treat-
ments changed the dynamics at the dose given, leading to altered
rates of specific cell state transitions. In the particular case of TMZ,
we saw an increased flux from the progenitor state 2, to state 5.
State 5 is enriched for OPC signatures and mesenchymal transition
signature, both of which are potentially associated with increased
tumor cell motility (Kessaris et al, 2006; Iwadate, 2016). Using
eigendecomposition, the STAG model could predict long-term state
composition. Such analyses suggested that blocking transitions to
state 5 might potentiate TMZ therapy (Fig 6F and G). An interesting
future direction is therefore to identify such a blockade against state
5 transitions. Of note, our results do not imply that depletion of the
top state would exhaust the GBM culture. They rather point toward
a preferred cellular state organization in the unperturbed in vitro
milieu with a large potential of adaptive plasticity. We acknowledge
that the results may partly depend on the dose of each treatment.
Here, we preferred to use doses that reflect a likely in vivo dose in
patients (TMZ) and a low range dose where physiological effects
have been observed (BMP4). In principle, the STAG framework can
be adapted to make the changes in the STAG network dose-
dependent, which may be an interesting avenue for future work.
When constructing the STAG model, we took a reductionistic
approach and used a simplified system of 2D cultures of glioblas-
toma cells. The benefit of this approach is that a sufficient number
of cells can be randomly sampled to support the estimation of cell
state transitions. To the extent that state transitions and growth are
modulated by 3D growth, or invasion of, e.g., blood vessels,
immune cells, or other stromal components, these are obviously not
captured in a 2D cell culture. It is notable, though, that our detected
cell states overlap with gene signatures defined in clinical materials,
embryonal brain, and other systems (Figs 3 and 5). An in-depth
discussion of cell number and the benefits and disadvantages with
2D cultures is included in the Appendix. The application of STAG to
the 3D culture setting, with appropriate computational extensions,
is reserved for future work.
In the presented strategy, single-cell lineage tracing is imple-
mented in a pooled setting from which cells are sampled at
random. The two benefits of this are that it permits a relatively
unbiased detection of cell states present in the culture, as well as
separate estimates of transitions and growth parameters of each
state. Subcloning schemes, by comparison, will focus predomi-
nantly on the subset of cells that can clonally expand in solitude
(14–49%, Segerman et al). It is, however, important to apply STAG
with an awareness of technical factors and choices that can poten-
tially influence the results. Such factors include the experimental
design (see Appendix) as well as the processing of the single-cell
data, and the definition of cell states. For instance, when process-
ing the RNA data, we here use cell cycle normalization based on
the method by Butler et al (2018), designed to remove differences
between cells in various cell cycle phases while maintaining the
difference between cycling and non-cycling cells. In the context of
our data, this method conserved phenotypically relevant signals
(such as the up-regulation of cell cycle genes in fast-growing state
2 in U3065MG cells, c.f. Fig 3). In contexts where distinctions
between cell cycles phase are essential, we would recommend
using STAG without cell cycle correction. To identify states, we
have used unsupervised clustering, commonly used within the
GBM field (e.g., Phillips et al, 2006; Verhaak et al, 2010; Neftel
et al, 2019). In principle, STAG could also be used with external
state definitions, using ssGSEA to assign each cell to a state based
on other predefined signatures. Last, an important analytical
choice is the number of states. Here, the number of states was
chosen as 6, in each cell line analyzed, based on data-driven
considerations (Appendix Figs S3, S5, and S6). We find that
network structures are overall kept intact with variations in cluster
number, e.g., 5 or 7 clusters (Figs EV2 and EV5) and can detect
biologically relevant signatures representing each state, substanti-
ating the validity of our approach.
◀ Figure 6. Employing the transition networks for assessing and predicting therapeutic interventions.
A Experimental design for U3065MG treatment experiments.
B STAG estimates of the state-specific growth rates for untreated U3065MG cells, and cells treated with BMP4 and TMZ. Error bars indicate the 90% confidence
interval, based on 1,000 bootstrap replicates.
C Estimated network of state transitions in the untreated U3065MG cells. The thickness of the arrows correlates with the rate of transition (number of transitions per
day).
D Estimated network of state transitions for BMP4- and TMZ-treated U3065MG cells. Red indicates increased rate of transitions compared with untreated cells. Blue
indicates decreased rate of transitions compared with untreated cells. Gray indicates transitions of the untreated network.
E Conceptual image of how the STAG-derived A-matrix can be expressed as eigenvalues and eigenvectors, interpreted as measures of population stability and state
equilibria, respectively.
F Eigenvalues of the state transition network of TMZ-treated U3065MG cells and the predicted minimal intervention to obtain bounded growth in each case.
G Predicted state equilibria for U3065MG cells in untreated condition and treated with BMP4 or TMZ.
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Looking ahead, we see several potential applications and
generalizations of STAG for cancer studies. In GBM, applying our
procedure across a broader set of patient samples and drugs
would help elucidate how cell state transitions differ across
patient subgroups and also explore if and how different classes
of targeted drugs change state transition rates. Potentially, such
an extended study may open for targeted interventions aimed at
re-distributing cell states (c.f. Fig 6F and G). Extending the STAG
algorithm itself, important directions include the investigation of
non-linear versions of the model, and extending the model to
capture, e.g., drug dose-dependent changes in cell STAG rates.
The STAG software is freely available at GitHub. The provided
modeling framework is not limited to glioma models; it can be
applied to data sets generated from any cancer model using the
described lentiviral barcoding strategy. STAG is designed to run
with any number of time points (2 or more). Considering that
tumor plasticity is a widely observed phenomenon in experimen-
tal oncology, we foresee that STAG will be applied to other forms





The Perturb-seq GBC library was a gift from Jonathan Weissman
(Addgene ID #85968) (Adamson et al, 2016). The library was
expanded in NEB® 5-alpha electrocompetent E. coli (New England
Biolabs, Ipswich, MA) according to the manufacturer’s protocol,
ensuring at least a 100× coverage to maintain library diversity. To
produce lentivirus, library plasmids were co-transfected with plas-
mids pLP1, pLP2, and VSVg (5 μg/ml of each, Thermo Fisher Scien-
tific, Boston, MA) using PEI (100 μg/ml, PolySciences, Warrington,
PA) into HEK293T packaging cells. Virus supernatant was collected
at 48 and 72 h after transfection, and virus was purified by ultracen-
trifugation at 72,000 g for 2 h, for 2 h, re-suspended in DMEM/F12
(Thermo Fisher Scientific), and stored in aliquots at −80°C until
use.
Human glioblastoma cell culture
U3017MG, U3065MG, and U3071MG cells were obtained from the
Human Glioblastoma Cell Culture (HGCC) Biobank (Xie et al,
2015) and cultured adherently on laminin (Sigma-Aldrich, St.
Louis, MO)-coated plates in a 1:1 mix of Neurobasal and DMEM/
F12 medium supplemented with B27 (without retinoic acid) and
N2 (Thermo Fisher scientific) and human recombinant EGF and
FGF2 (10 ng/ml, PeproTech, Rocky Hill, NJ). For cell detach-
ment, StemPro Accutase (Thermo Fisher scientific) was used. Cell
line authenticity was confirmed by STR profiling, and the cell
lines displayed no mycoplasma contamination (Eurofins Geno-
mics). Tumor sample collection was approved by the Uppsala
regional ethical review board, number 2007/353; informed
consent was obtained from all subjects included. Experiments
conformed to the principles set out in the WMA Declaration of
Helsinki and the Department of Health and Humans Services
Belmont Report.
Growth rate determination
To determine the growth rate at the cells exponential growth phase,
non-barcoded cells were seeded in quadruplicate wells at five dif-
ferent starting densities ranging between 8 and 500 cells/mm2. Cells
were kept for up to 13 days with readouts of cell count at days 1, 3,
6, 8, 10, and 13 using Trypan blue exclusion on Countess Cell
Counting Chamber Slides (Invitrogen) or alamarBlue Assay (Invitro-
gen). 95% confidence intervals were determined using GraphPad
Prism 6.
Barcoding procedure
Human glioblastoma cells between passages 6 and 12 were infected
with the Perturb-seq lentiviral library. Functional virus titer was
determined by measuring the percentage of BFP-positive (BFP+)
cells by flow cytometry for each cell line. To minimize potential off
target effects of the lentiviral tagging and to ensure accurate esti-
mates of cell state changes, a multiplicity of infection of < 0.1 was
used, rendering single barcodes in more than 95% of barcoded cells
(see Appendix for details). Briefly, cells were incubated with the
lentivirus as a single-cell suspension in 20 μl of media for 4 h at
37°C and seeded onto a laminin-coated 60-mm dish. The next day,
virus-containing media was replaced with fresh media. Cells were
then allowed to propagate for 4–7 days. At experimental day 0,
2,500 BFP+ cells were sorted into one well on a 96-well plate, giving
an expected 96.7% of cells with a unique barcode combination,
according to calculations based on (Lan et al, 2017) (see Appendix
for details). To confirm this, the remaining unsorted cells were
frozen down in media with 10% DMSO in −150°C and later
subjected to single-cell RNA sequencing. To verify that barcoding
itself having a strong effect on states, we compared barcoded vs
non-barcoded cells and found no differentially expressed pathways
(Appendix).
Time series experiment
For U3065MG, barcoded cells were detached at experimental day
7 and 14. 80% of the cells frozen down, while the remaining 20%
were seeded into a new well. After 21 days at the experimental
endpoint, all cells were frozen down. For U3017MG and
U3071MG, harvested cells were freshly prepared for single-cell
RNA sequencing and samples were obtained for experimental days
7 and 14.
Drug treatment experiment
At day 8, barcoded U3065MG cells were detached and 70% of the
cells were frozen down. The remaining cells were equally divided
into three new wells on a 96-well plate. When attached, cells were
treated every second day with 1 ng/ml BMP4 (Thermo Fisher Scien-
tific), 1 μg/ml Temozolomide (Sigma-Aldrich) or remained
untreated. At day 16, cells from all wells were frozen down.
FACS sorting and flow cytometry
Cells were detached using TrypLE Select (Thermo Fisher scientific),
pelleted, and re-suspended in FACS buffer (0.5% BSA/2 mM EDTA
in PBS), followed by staining with fluorophore-conjugated antibod-
ies for 20 min, 4°C. Antibodies used were CD24-BV421 (BD
PharMingen, #562789), CD44-FITC (BD PharMingen, #555478), and
HLA-DR-APC-Vio770 (Miltenyi Biotec, #130-111-792). Isotype
control antibodies for each fluorophore were from the same
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companies as the primary antibodies. Cell sorting was performed on
a BD FACSAria III Cell Sorter and flow cytometry on a BD LSR
Fortessa instrument (BD Biosciences, for instrument settings, see
Appendix Supplementary methods). Data analysis was performed
using the Kaluza Analysis Software (Beckman Coulter). The optical
configuration on the BD FACSAriaIII cell sorter and the BD LSR
Fortessa flow cytometer is presented in Table S2.
Single-cell RNA sequencing
Single-cell RNA sequencing libraries were prepared using the Chro-
mium Single Cell 30 Library Gel Bead Kit v3 according to the manu-
facturer’s instructions (10× Genomics). Cryo-preserved cells were
washed and re-suspended in 0.1% BSA in PBS immediately before
loading on a Chromium Single Cell B Chip (10× Genomics), with a
target capture of 10,000 cells. Libraries’ quality was assessed using
the Agilent BioAnalyzer High-Sensitivity DNA assay then sequenced
using Illumina’s NextSeq 500 platform.
Computational methods
Data processing
The data were processed before further analysis in R (R Core Team,
2019) using the package Seurat (Butler et al, 2018). Cells containing
less than 500 genes and genes present in less than 3 cells were fil-
tered out, and data were log normalized and row centered. To
prevent the downstream analysis from only capturing cell cycle
dynamics, the difference in cell cycle phase between cells was
removed from the data by following the workflow proposed by
Seurat (Butler et al, 2018). Each cell was assigned scores based on
gene markers for the S- and G2/M-phases, and the difference
between these scores was regressed out.
Differential expression analysis between large and small clones
Cells were classified as small, intermediate, or large clones based on
their associated barcodes. Small clones were defined as those
containing a barcode present in ≤ 6 cells, large clones contained a
barcode present in ≥ 17 cells, and intermediate clones contained
barcodes present in cells in between these numbers. The cutoff
values were chosen to obtain equally sized groups. A two-sample
t-test was performed to identify genes that were differentially
expressed between the large and small clones. GeneIDs and
t-statistics were extracted for all genes with FDR < 0.25 and used to
create a ranked list. This was subsequently submitted to GSEA in
the pre-ranked mode using default parameters. In addition to the
hallmark gene sets from the MSigDB collections, gene signatures
defining stemness (Patel et al, 2014) and transcripts regulated by
the transcription factor SOX2 (Singh et al, 2017) were included in
the GSEA analysis.
Deciding number of states
For determining the optimal number of clusters (k) in which to
partition the data, consensus clustering and bootstrap network
estimation were used. To start with, consensus clustering for
k = 2–8 was done using the R-package ConsensusClusterPlus
(Wilkerson & Hayes, 2010). 80% of the cells were sampled from
the data set and clustered using k-means. This process was
repeated 100 times. Appendix Fig S3A shows the generated
consensus matrices for k = 2–8 and Appendix Fig S3B a plot
showing the relative change in the cumulative distribution func-
tion (CDF) curve.
Based on the consensus clustering results, bootstrap network
estimation was carried out for k ≥ 4. Again, 80% of the cells were
sampled and the transition network was estimated, this process was
repeated 100 times for k = 4–8. Model robustness was scored by
calculating the consistency of growth rate values between runs
(Appendix Fig S3C).
For the additional cell lines U3017MG and U3071MG, cluster
number was decided based on results from the consensus clustering
performed using the R-package ConsensusClusterPlus (Wilkerson &
Hayes, 2010), Appendix Figs S5 and S6.
Definition and initial assignment of cells into
transcriptional states
Cells were divided into states based on their gene expression using
the k-means clustering algorithm in R. Marker genes for each state
were defined through differential expression analysis in Seurat using
the test MAST (Finak et al, 2015). GeneIDs and log2FC-values were
extracted for all genes with adjusted P-value < 0.01 and used to
create ranked gene lists for each state. These were subsequently
submitted to GSEA in pre-ranked mode using default parameters. In
addition to the hallmark gene sets from the MSigDB collections,
gene signatures derived from various publications were used, and
pmid is indicated in Fig 3A.
State assignment using single-sample scoring
The R-package singscore (Foroutan et al, 2018) was used to score
individual cells in the drug treatment experiment against gene signa-
tures derived from the previously defined states. Cells were assigned
to the state with the highest obtained score. For the integration of
single-sample scoring with the established computational pipeline
for analyzing barcoded data, we implemented the singscore algo-
rithm in MATLAB.
Time-dependent transition and growth model
At a given time point t, we model the population of GBM cells as
the tuple XðtÞ¼ fX1, X2, :::XkgðtÞ, where each XiðtÞ is the number
of cells in transcriptional state i at time t. In a given time interval,
δt, each individual cell can undergo three types of discrete events:
• Growth, Xi !Xiþ1, with rate constant αi
• Death, Xi !Xi1 with rate constant βi
• Transition between states i and j, ðXi, XjÞ! ðXi1, Xjþ1Þ with
rate constant γji
From a given starting state (e.g., 14, 0, and 4 cells in states 1, 2,
and 3, respectively), this model can be forward-simulated using
Gillespie’s method (Gillespie, 1976) to yield a sample of how
X1, X2, ::: evolve over time. Here, we are interested in the inverse
problem, i.e., a situation where X1, X2, ::: are observed at several
time points but where the parameters (α, β, γ) are unknown. One
approach to estimate the parameters is to employ Markov chain
Monte Carlo methods (MCMC). This, however, is computationally
costly. For an efficient approximate estimation, we employ the
following continuum approximation. If we view the vector X as
concentrations rather than counts, which is a good approximation
for higher values of X, we can model the growth and transitions as
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i.e., the rate of change in cells in state i is a function of growth,
death, and transitions to/from that state. This set of linear first-




X tð Þ¼AX tð Þ: (7)
The elements of A¼faijg are aij ¼ γij when i ≠ j and
aij ¼ αiβi∑k≠jγkj when i¼ j. The solution is given by (e denoting
a matrix exponential):
X tþδtð Þ¼ eAδtX tð Þ: (8)





where ηs is the fraction of cells used for sequencing at each time
point ts, s¼ 1, 2, 3 (7, 14, and 21 days, respectively). Using a first
degree approximation of the matrix exponential, eAt ≈ IþAt, the







which is solved by optimization to yield an estimate of A, from
which estimates of γij and the growth parameters ri ¼ αiβi are
obtained. Important to note here is that the linear approximation
of the system allows us to formulate this as a regression problem,
which has a unique solution as X is full rank.
The specific optimization problem solved is as follows:
min
A








aij ≥ 0, i≠ j
: (11)
Note that non-diagonal elements of A = {aij} are constrained to
non-negative values (because they are rates) and that the sum of
absolute values is constrained to ensure sparsity of the solution (a
so called l1 or lasso penalty). The solution is obtained in MATLAB
using the CVX solver (cvxr.com).
Effects of treatments on network parameters
We represent treatments as perturbations of the model parameters, i.e.,
A¼AjointþΔAtreatment (12)
Accordingly, we can define a global error across all treatments as
EglobalðX, A, ΔA1, ΔA2, :::Þ¼ ∑
t∈ treatments
EðXt, AþΔAtÞ (13)
The associated optimization problem is.
min
A, ΔA1, ΔA2, ...
Eglobal X, A, ΔA1, ΔA2, :::ð Þ
s:t: jjA nd jj1 ≤ λ1
jjA nd þΔAndi jj1 ≤ λ2, i¼ 1, 2, . . .
And ≥ 0
AndþΔAndi ≥ 0, i¼ 1, 2, . . .
jjAAprijjFro ≤Ω
: (14)
where notation And denote matrix A with diagonal elements set to
zero, i.e., the non-diagonal part of A. The first two constrains
impose sparsity on the joint network and the treatment-specific
networks, respectively. The following two constraints ensure non-
negativity of the rates in the joint and treatment-specific networks,
respectively. The last constraint is the tolerated deviation of A from
a prior transition matrix. This is an optional constraint, and the
deviation is defined by the user. The solution is obtained in
MATLAB using the CVX solver (cvxr.com).
Cross-validation for tuning lasso penalties
To decide the lasso penalty for the baseline network, the original
(untreated) data set was split in two, one training and one test set.
The matrix A was solved for the training set for values of the lasso
penalty from 0.5 to 2 and for each value, and the distance to the test
set (error) was calculated. The same procedure was done to decide
the second penalty but using the data from the treatment experi-
ment (Appendix Fig S7).
Benchmarking the transition and growth model
A large number of simulations were performed to assess the validity
of our model in the following manner.
The Gillespie algorithm (Gillespie, 1976) was used to simulate
synthetic data sets using user-defined transition and growth rates.
These were random but chosen to generate a mean rate in the
matrix to around 0.03 days−1. Our model was fitted to the simulated
data set and all transition and growth rates were estimated, emulat-
ing the workflow for real data sets. The distance between the input
and output transition matrix (calculated as the Frobenius norm)
was calculated and used as a goodness-of-fit measure. The simula-
tions were done for several varying conditions, number of states
from 2 to 10 and for each number of state from one transition to a
fully connected network. For each connectivity value, the sampling
interval was varied from 1 to 10 days. However, the allowed
number of sampling times was kept fixed to three times and the
sampled fraction to 80% to ensure comparability between runs.
The results are visualized in Appendix Fig S2, showing one plot
for each number of states. The x-axis displays an increasing value
for the days between sampling, and the y-axis displays an increasing
value for the connectivity (number of links in the network). Values
plotted are the distance between input and output networks,
described above. From the plots, we see that for some sets of condi-
tions the model re-creates the transition matrix with high accuracy
(blue areas, low error), while other sets of conditions have a higher
estimation error (yellow areas, high error), e.g., in the cases where
we have many states and sampling is done at a too high or too low
frequency.
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Bootstrapping
Bootstrapping was used to estimate confidence intervals for
growth rates derived from the STAG model (Figs 2F and 6B). A
random data set of the same size as the original data set (XðtÞ,
described above) was constructed by sampling with replacement
from the original data set. The growth rates were estimated using
the STAG model. The process was repeated 1,000 times, and the
confidence intervals were calculated based on the bootstrap
outputs.
Galton–Watson model
To relate the per-barcode cell counts in Fig 1C to a Galton–Watson
process, we carried out a simulation, in which we started with a
hypothetical population of cells, each carrying 1 barcode (Fig 1D,
day 0). We subsequently simulated a 1-state version of our model
(with growth rate α¼ 0:2=day and death rate β¼ 0:03=day, no tran-
sitions) and used Gillespie’s algorithm to simulate a distribution of
cells per barcode (Fig 1D, day 7–day 21). The simulation used a
number of barcode (1,217) and assumed that 80% of cells were
harvested for sequencing each week, as in our experimental
protocol.
Validation in external data sets
We retrieved transcriptomic profiles and matched survival data for
501 GBM patients from the TCGA cohort (Brennan et al, 2013). Each
patient in the data set was scored against our derived state signa-
tures using the ssGSEA method from the R-package gsva (H€anzel-
mann et al, 2013). Cox’s proportional hazards models were
generated using the enrichment score of each state as independent
predictor, with clinical covariates (age at diagnosis and gender)
included. To relate our cell state signatures to embryonic human
brain signatures, we used the data from Eze et al (2021), obtained
from (https://cells-test.gi.ucsc.edu/?ds=early-brain). We used the
61 clusters provided by the authors. The mean Carnegie age of each
cluster (Fig 5B) was calculated as the average Carnegie stage of all
cells belonging to that cluster. We computed the overlap between
the embryonic clusters (genes with log fold change > 0.25 in each
respective embryonic clusters 1–61) and our state signatures (genes
with log fold change > 0.25 in each of our cell state signatures) by
Fisher’s exact test. When the gene set overlap was higher than
expected, the enrichment score was logðPÞ (i.e., a positive
number), where P is the Fisher P-value (red in Fig 5B). Conversely,
when the gene set overlap was smaller than expected, the enrich-
ment score was defined as þlogðPÞ (i.e., a negative number.). We
thus obtained a profile for each state in terms of enrichment scores,
which was correlated with mean Carnegie time (Spearman correla-
tions, Fig 5B).
Stability analysis




subject to AþΔA is stable: (15b)
To solve this problem, we used a convex stability criterion
(Box 1, equation 5), based on stability (Zavlanos et al, 2011).
Steady-state distribution
Consider a short time interval between t and t + dt. Then, y
(t + dt) = y(t) + y0(t)dt + ε (where the residual ε can be made arbi-
trarily small by reducing dt). Since y0(t) = Ay(t), we have the
following:
y tþdtð Þ¼ IþAdtð Þy tð Þþ ɛ: (16)
If the relative proportions of the states are at equilibrium at time
t, this is the same as saying that y(t + dt) = ky(t), i.e., y(t) merely
scales by a constant k.
kyðtÞ¼ ðIþdtAÞyðtÞ (17)
Call the solution to this equation v¼ yðtÞ. If we apply the substi-
tution k¼ 1þ λdt (where λ is some constant), we obtain.
ðIþλdtÞv¼ðIþAdtÞv (18)
which simplifies to the eigenvector equation
λv¼Av: (19)
In other words, even when the cell population grows, there can
be a steady state of the relative proportions of the states. When such





where v is a real, non-negative eigenvector of A. The
existence and uniqueness of such a steady state of proportions,
for a given matrix A, is a nuanced question. Generally, if all
states are connected and all have positive growth (ie all entries
of A are positive), the Perron–Frobenius theorem says that a
real-valued, positive eigenvector v exists. The solution is not
guaranteed to be unique. For instance, for an identity matrix
(no transitions) any state composition is a proportional steady
state.
Data availability
The data sets and computer code produced in this study are avail-
able in the following database




• STAG model: Github (https://github.com/idalarsson/STAG)
• Code used to conduct analyses:
https://figshare.com/projects/Modeling_glioblastoma_heteroge
neity_as_a_dynamic_network_of_cell_states/113166
Expanded View for this article is available online.
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